Correcting Hyperkalemia in CKD: Examining Current and Emerging Treatment Options
ISN Academy. Roger S.
Apr 24, 2019; 272232
Topic: Chronic kidney disease
Simon Roger
Simon Roger
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
Treatment options for hyperkalemia have been essentially unchanged since the 1960s, when the cation exchange resin, sodium polystyrene sulfonate (Kayexalate) was introduced. This session will provide a brief discussion of the traditional treatment interventions used for chronic hyperkalemia, such as dietary restriction, changes in medications, treatment of exacerbating metabolic abnormalities and sodium polystyrene sulfonate (Kayexalate), followed by a review of newer treatment options. The emergence of new oral potassium binders has resulted in the re-examination of therapeutic paradigms for chronic hyperkalemia management. The efficacy and safety of new potassium binders (e.g. patiromer and zirconium cyclosilicate) for chronic management of hyperkalemia was tested and proven in several randomized controlled clinical trials, which have also showed that it is possible to maintain RAASi therapy over extended periods of time while avoiding the re-emergence of hyperkalemia. The introduction of safe and effective long-term hyperkalemia treatment options addresses the previous limitations on RAASi utilization leading to improved optimization of patient care.
Expected Learning Outcomes:
Following are learning outcomes expected from the audience at the conclusion of this symposium.
  • Emphasis will be placed on these learning objectives and changes in practice. Examine the prevalence of and risk factors for hyperkalemia and its associated prognosis across healthcare settings
  • Appraise the recent shifts in treatment patterns that have occurred in the management of anemia in CKD
  • Describe commonly applied therapies for anemia and hyperkalemia and understand their advantages and disadvantages.
  • Become familiar with novel treatments for hyperkalemia and anemia, and their role in changing therapeutic paradigms optimizing management.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings